Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1374051
                    [Title] => New therapies provide optimism in chronic HCV
                    [Summary] => 
Chronic hepatitis C virus infection is currently responsible for more US deaths than HIV; is complicated to treat; is not vaccine preventable; and is a major driver of liver transplants, cirrhosis, chronic and end-stage liver disease, and liver cancer.

                    [DatePublished] => 2014-09-28 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 514848
                    [Title] => Liver grafts from older donors yielded good outcomes
                    [Summary] => 
Using selected organ donors aged 60 years or older had no deleterious short- or medium-term effects, according to a single-center review of 489 liver transplants done over a 10-year period.
                    [DatePublished] => 2009-10-18 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 70204
                    [Title] => Update on chronic hepatitis C
                    [Summary] => 
            
                    [DatePublished] => 2008-06-29 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 299580
                    [Title] => Primary liver cancer: Worldwide incidence and trends
                    [Summary] => 
(Conclusion)
In Egypt, the reported prevalence of HCV infection in the population has been estimated to be of the order of six percent to nine percent in urban areas and 27 percent to 30 percent in the rural parts of the Nile delta. Epidemiologic studies have traced the source  of HCV infection to the large scale treatment campaigns against schistosomal infestation conducted between 1920 and 1970.
                    [DatePublished] => 2005-10-02 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 275976
                    [Title] => Can cirrhosis or cancer be prevented with interferon/ribavirin in chronic viral hepatitis?
                    [Summary] => The incidence of hepatocellular cancer (liver cancer) is rising rapidly. According to Surveillance, Epidemiology and End Results (SEER) analyses, liver and intrahepatic biliary cancer rates are increasing at a faster rate than any other cancer-related death. Once a patient is diagnosed clinically, the average life expectancy is less than one year.


                    [DatePublished] => 2005-05-01 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 267041
                    [Title] => Current status of HCV therapy
                    [Summary] => Major advances have been made in the treatment of chronic hepatitis C during the last 10 years, but major challenges remain, since treatment with pegylated interferons and ribavirin is effective in only around 55 percent of patients. Newer therapies are needed for the increasing numbers of patients who do not respond to relapse after current treatments with pegylated in interferons and ribavirin.


                    [DatePublished] => 2004-12-05 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 228945
                    [Title] => Hepatitis C causes neurotoxic ‘brain fog’
                    [Summary] => HCV linked to impaired cognition, decreased motor function. Patients with chronic hepatitis C frequently report a persistent lassitude, or "brain fog", that seriously impairs their functioning. To this end, Canadian researchers have discovered organic brain abnormalities in these patients that suggest a direct link between cerebral dysfunction and hepatitis C, regardless of disease severity. Additional study results show that almost half of patients with even mildly fibrotic hepatitis C virus (HCV) develop impaired learning ability, and one in six suffer from reduced motor skills.
                    [DatePublished] => 2003-11-23 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

HCV

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1374051
                    [Title] => New therapies provide optimism in chronic HCV
                    [Summary] => 
Chronic hepatitis C virus infection is currently responsible for more US deaths than HIV; is complicated to treat; is not vaccine preventable; and is a major driver of liver transplants, cirrhosis, chronic and end-stage liver disease, and liver cancer.

                    [DatePublished] => 2014-09-28 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 514848
                    [Title] => Liver grafts from older donors yielded good outcomes
                    [Summary] => 
Using selected organ donors aged 60 years or older had no deleterious short- or medium-term effects, according to a single-center review of 489 liver transplants done over a 10-year period.
                    [DatePublished] => 2009-10-18 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 70204
                    [Title] => Update on chronic hepatitis C
                    [Summary] => 
            
                    [DatePublished] => 2008-06-29 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 299580
                    [Title] => Primary liver cancer: Worldwide incidence and trends
                    [Summary] => 
(Conclusion)
In Egypt, the reported prevalence of HCV infection in the population has been estimated to be of the order of six percent to nine percent in urban areas and 27 percent to 30 percent in the rural parts of the Nile delta. Epidemiologic studies have traced the source  of HCV infection to the large scale treatment campaigns against schistosomal infestation conducted between 1920 and 1970.
                    [DatePublished] => 2005-10-02 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 275976
                    [Title] => Can cirrhosis or cancer be prevented with interferon/ribavirin in chronic viral hepatitis?
                    [Summary] => The incidence of hepatocellular cancer (liver cancer) is rising rapidly. According to Surveillance, Epidemiology and End Results (SEER) analyses, liver and intrahepatic biliary cancer rates are increasing at a faster rate than any other cancer-related death. Once a patient is diagnosed clinically, the average life expectancy is less than one year.


                    [DatePublished] => 2005-05-01 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 267041
                    [Title] => Current status of HCV therapy
                    [Summary] => Major advances have been made in the treatment of chronic hepatitis C during the last 10 years, but major challenges remain, since treatment with pegylated interferons and ribavirin is effective in only around 55 percent of patients. Newer therapies are needed for the increasing numbers of patients who do not respond to relapse after current treatments with pegylated in interferons and ribavirin.


                    [DatePublished] => 2004-12-05 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 228945
                    [Title] => Hepatitis C causes neurotoxic ‘brain fog’
                    [Summary] => HCV linked to impaired cognition, decreased motor function. Patients with chronic hepatitis C frequently report a persistent lassitude, or "brain fog", that seriously impairs their functioning. To this end, Canadian researchers have discovered organic brain abnormalities in these patients that suggest a direct link between cerebral dysfunction and hepatitis C, regardless of disease severity. Additional study results show that almost half of patients with even mildly fibrotic hepatitis C virus (HCV) develop impaired learning ability, and one in six suffer from reduced motor skills.
                    [DatePublished] => 2003-11-23 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

New therapies provide optimism in chronic HCV

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | September 28, 2014 - 12:00am

Chronic hepatitis C virus infection is currently responsible for more US deaths than HIV; is complicated to treat; is not vaccine preventable; and is a major driver of liver transplants, cirrhosis, chronic and end-stage...

Opinion

Liver grafts from older donors yielded good outcomes

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | October 18, 2009 - 12:00am

Using selected organ donors aged 60 years or older had no deleterious short- or medium-term effects, according to a single-center review of 489 liver transplants done over a 10-year period.

Opinion

Update on chronic hepatitis C

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | June 29, 2008 - 12:00am

Opinion

Primary liver cancer: Worldwide incidence and trends

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | October 2, 2005 - 12:00am

(Conclusion) In Egypt, the reported prevalence of HCV infection in the population has been estimated to be of the order of six percent to nine percent in urban areas and 27 percent to 30 percent in the rural parts...

Opinion

Can cirrhosis or cancer be prevented with interferon/ribavirin in chronic viral hepatitis?

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | May 1, 2005 - 12:00am

The incidence of hepatocellular cancer (liver cancer) is rising rapidly. According to Surveillance, Epidemiology and End Results (SEER) analyses, liver and intrahepatic biliary cancer rates are increasing at a faster...

Opinion

Current status of HCV therapy

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | December 5, 2004 - 12:00am

Major advances have been made in the treatment of chronic hepatitis C during the last 10 years, but major challenges remain, since treatment with pegylated interferons and ribavirin is effective in only around 55...

Opinion

Hepatitis C causes neurotoxic ‘brain fog’

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | November 23, 2003 - 12:00am

HCV linked to impaired cognition, decreased motor function. Patients with chronic hepatitis C frequently report a persistent lassitude, or "brain fog", that seriously impairs their functioning. To this...

Opinion